Baidu
map

Pharm Biol:冠心V号合剂通过调节铁稳态减轻心肌缺血再灌注损伤

2022-10-24 紫菀款冬 MedSci原创

研究冠心V(GX)对心肌缺血再灌注损伤(MIRI)的心脏保护作用,并探讨其可能的机制。

背景:冠心V(GX)由著名的中药复方生脉散改良而成,其中党参、麦冬和五味子擅长益气、滋阴和促进体液的生成,丹参、赤芍和地黄可以活血化瘀,促进体液生成。因此,GX可用于补气、养阴、促进血液循环,这意味着其在心肌缺血再灌注损伤(MIRI)治疗中的巨大潜力。然而,其对MIRI的保护作用尚不清楚。

目的:研究GX对MIRI的心脏保护作用,并探讨其可能的机制。

方法:将SD雄性大鼠分为Sham、MIRI和MIRI + GX组。在大鼠缺血再灌注(IR)手术前7天 ,给予GX(6 g/kg)灌胃处理。评估梗死面积、组织病理学、血清酶活性、心肌线粒体超微结构。

H9c2细胞用GX(0.5 mg/mL)提前处理,然后暴露于缺氧/复氧(HR)。测定细胞活力和LDH水平。网络药理学被用来预测潜在的机制。使用TCMSP数据库、DrugBank数据库等预测GX的相关靶点。最后,通过药理实验验证预测结果。

结果:GX显著降低心肌梗死面积,从56.33%降至17.18%,降低AST水平(239.32 vs. 369.18 U/L)、CK-MB(1324.61 vs. 2066.47 U/L)和LDH(1245.26 vs. 1969.62 U/L)和减少线粒体损伤,GX显著提高H9c2细胞存活率(IC=3.913 mg/mL),并抑制LDH的释放(207.35 vs. 314.33)。

结论:GX可通过调节铁稳态来减轻MIRI,提示GX可能是治疗MIRI的潜在候选药物

 

文献来源:

Zhou F, Zhang Z, Wang M, et al. Guanxin V attenuates myocardial ischaemia reperfusion injury through regulating iron homeostasis. Pharm Biol. 2022;60(1):1884-1898. doi:10.1080/13880209.2022.2123934

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2096192, encodeId=952220961928c, content=为中医药喝彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096191, encodeId=e4e720961919d, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:21 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096190, encodeId=b0c4209619051, content=中国原研,突出中医药特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096189, encodeId=497c209618930, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:38:51 CST 2022, time=2022-10-26, status=1, ipAttribution=)]
    2022-10-26 delianjihui

    为中医药喝彩

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2096192, encodeId=952220961928c, content=为中医药喝彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096191, encodeId=e4e720961919d, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:21 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096190, encodeId=b0c4209619051, content=中国原研,突出中医药特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096189, encodeId=497c209618930, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:38:51 CST 2022, time=2022-10-26, status=1, ipAttribution=)]
    2022-10-26 delianjihui

    转发学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2096192, encodeId=952220961928c, content=为中医药喝彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096191, encodeId=e4e720961919d, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:21 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096190, encodeId=b0c4209619051, content=中国原研,突出中医药特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096189, encodeId=497c209618930, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:38:51 CST 2022, time=2022-10-26, status=1, ipAttribution=)]
    2022-10-26 delianjihui

    中国原研,突出中医药特色

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2096192, encodeId=952220961928c, content=为中医药喝彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:49 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096191, encodeId=e4e720961919d, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:21 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096190, encodeId=b0c4209619051, content=中国原研,突出中医药特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:39:16 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096189, encodeId=497c209618930, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Oct 26 02:38:51 CST 2022, time=2022-10-26, status=1, ipAttribution=)]
    2022-10-26 delianjihui

    学习受益

    0

相关资讯

TAG:铁剂在接受抗肿瘤坏死因子-α药物治疗的炎症性肠病患者中的作用

炎性肠病(IBD)是一种慢性炎性疾病,其主要形式为溃疡性结肠炎(UC)和克罗恩病(CD)。IBD的主要症状和体征在肠道。但是,肠外表现很常见。

Nat Chem Biol:南方医科大学全新发表文章:焦虑发生新机制

研究首次发现脑区间铁离子转运异常是焦虑发生的关键环节,为焦虑症发病机制的研究提供了新思路。

Sci Rep:类风湿性关节炎的血清铁调素水平、铁代谢和骨质疏松

这项研究表明,血清铁调素和血清铁与RA患者的骨质疏松有间接和直接关联。

Blood:抗BMP6抗体联合EPO治疗慢性病性贫血!

联合抗BMP6抗体和EPO治疗可改善全身铁供应,减少治疗ACD所需要的EPO量。 FPN水平对红细胞前体的调节导致细胞内游离铁水平降低,并促进红细胞成熟。

Oncotarget:靶向铁代谢为逆转卵巢癌耐药性提供新策略

Nrf2的诱导作用参与卵巢癌的顺铂耐药。SLC40A1(溶质载体家族40成员1)与铁浓度密切相关,研究提示其具有许多可能的Nrf2结合位点。

Infection: 铁超负荷会促进重症COVID-19患者的心脏损伤

铁死亡参与了心血管疾病的发生发展过程,如冠心病,心肌梗死缺血再灌注损伤以及心力衰竭等

Baidu
map
Baidu
map
Baidu
map